َAs the world enters the second year of the coronavirus pandemic, actionable insights are more critical than ever. They’re even being prioritized in the new National Strategy for COVID-19 Response and Pandemic Preparedness alongside executive orders to evaluate progress, monitor outcomes, and support transparency and equity with Americans. As the world rolls out COVID-19 vaccines, the need for accurate and timely vaccination distribution and uptake data is top-of-mind for government leaders, public health organizations, and healthcare providers everywhere.
These metrics are foundational for managing vaccination programs, measuring their effectiveness, and determining our collective progress toward “a blanket of herd immunity,” as described by Dr. Anthony Fauci, director, National Institute of Allergy and Infectious Diseases and chief medical advisor for the Biden Administration.
This is a “wartime effort,” as we’ve heard national leaders state recently, to protect population health—particularly the most vulnerable—as well as to contain the virus as we lower case counts toward zero and to restore Americans’ trust with different discourse. By creating public performance dashboards for more transparency and accountability, and prioritizing a data-driven approach in the efforts and decisions of federal, state and local governments, vaccine management analytics is already the data story of 2021.
Vaccine Management Analytics In The Spotlight
Effective management of any vaccine distribution program requires a holistic picture of the vaccine supply chain, the populations being prioritized, the success rate in reaching those populations, and the strengths and weaknesses of the metrics used to measure progress and performance.
On the path to recovery, government leaders, the public and private sector, and healthcare providers have realized that vaccine administration and management is a complex, evolving process. Expecting we could implement it overnight with a one-size-fits-all approach was unrealistic—some may say foolish—and we must ask some of these important questions as we press forward:
- Where is the greatest vaccine reluctance based on rate of spread and case count?
- How do we prioritize population groups for immunization and maintain equity?
- What level of awareness and understanding exists around vaccine safety and efficacy?
- How does vaccine supply match demand?
- In which direction are immunizations tracking and impacting COVID spread?
- Are vaccine sites known and sufficiently equipped and staffed?
As we create the path to normalcy, with increased access, use and communication with data and analytics, we can elevate our national and local pandemic response and make better vaccine management decisions that have a national and global impact.
For several months, I’ve conversed with government leaders and health officials, considering their concerns and questions and discussing how data analytics can assuage them. With those engagements top-of-mind, I’d like to highlight:
- Some effective vaccine management dashboard examples that states are leveraging for their needs and situations
- How some states are using data and analytics to achieve positive outcomes
Using Data To Guide COVID-19 Vaccine Management
The national vaccine effort is one of the greatest operational challenges America has faced. As we prioritize data and visual analytics in our response and resolution, our learnings can help frame how we approach future events and crises. The dashboard examples that I’ll share, containing sample data, demonstrate how data informs vaccine management, but the same analytics principles and approach could be applied to management of other national challenges.
Tracking Performance Against Vaccine Goals
Do you need to pivot local attention to track down more vaccines or other treatment supplies? Are mortality rates on the rise, unexpectedly? Is there a certain community that needs increased attention? Do we need additional marketing and public outreach to overcome vaccine reluctance and hesitancy? These questions and more are weighing on the minds and hearts of our leaders and public health officials and can be explored through solutions like a performance management dashboard, shown below.
By tracking performance in this way, it’s easier to take a snapshot of local progress to see if a state will meet, exceed or fall short of vaccine goals. It is also an effective communication tool for governors, mayors or county executives to be transparent with constituents and the public in their briefings and updates.
Furthermore, with increased plans to expand vaccine manufacturing and purchases, and improve national allocation, distribution, administration and tracking, there will be more data for government leaders to capture, monitor and share for a clearer sense of how localized efforts impact national goals, benchmarks and reporting.
Assessing The Readiness Of Facilities To Administer Vaccines
This dashboard reflects the readiness of mass vaccine deployment across cities, counties and states because hospitals, medical clinics, pharmacies and other locations have fulfilled administration requirements.
Monitoring COVID-19 Spread In Communities
With data and analytics, communities can assess resources, know when to order supplies, determine vaccine administration and help leaders understand where to focus their efforts. The sample dashboard below is one example of this, providing a high-level view and giving the option to drill down into certain areas to understand where numbers are higher or lower and determine the best course of action.
Vaccine Management Analytics In Action, Creating Benefit In Local Communities
Each week brings new problems that sometimes compound into more complex problems, so “we can’t take any chances and need to put data to the test,” explained Anthony Young, senior manager, solution engineering, U.S. Public Sector at Tableau Software. After nearly a year of capturing, analyzing and determining where we can gain insights from COVID data, using a data-driven approach with vaccine management will continue to create positive outcomes. For example:
- Improved patient engagement and understanding of their vaccination responsibility so they successfully follow through with immunization
- Clearer, more direct, and proactive communication with stakeholders
- Increased public transparency so people are confident they’re receiving good, truthful data
- Improved management of vaccination workflows and operations based on demand and need
- More equitable vaccination through better population prioritization
- Improved tracking and monitoring with populations of interest
Two government agencies are tracking, analyzing and putting data to work in their own pandemic responses as they focus on keeping citizens informed, engaged safe, and healthy.
- The Ohio Department of Health published a dashboard, built by the Department of Administrative Services’ InnovateOhio Platform, to keep citizens informed about current trends, key metrics, and its forecast for how mitigation policies will reduce strain on the healthcare system.
- The Lake County Health Department (LCHD) in Northern Illinois is tackling vaccine orchestration as it promotes resident health. Together with partners, LCHD launched Lake County AllVax Portal, an online vaccine registration and management system, as a single source of truth for the community to track inventory status, spot trends, pinpoint catalysts and inform vaccine resource planning.
“Transparency matters, and data and analytics will combat disinformation, providing the source of truth when citizens need it most,” explained Graham Stroman, my colleague and vice president of sales, U.S. State, and Local Government at Tableau Software. Let’s continue to make data analytics a central tool and effective mouthpiece in our COVID-19 efforts as Americans anxiously await a return to normalcy.
Let’s Rise To The Vaccine Management Challenge With Data And Analytics
March 2020 was more than a year ago, and so much has changed. Could we ever imagine that this is where we would be today? New terms are part of our everyday language: contact tracing, flatten the curve and social distancing. Just like putting on shoes and brushing our teeth, hand sanitizing and putting on masks are part of our daily routines.
Problems have grown and compounded, but innovative solutions, powered by data and analytics, have emerged to solve them and support better decision making and action. I urge the public and private sector, our government leaders and public health officials to continue looking for ways to lead with data.
To learn more about vaccine management analytics and how Tableau or other resources can help you visualize key insights to create a data-driven, effective vaccine response, visit the vaccine management resource page on Tableau.com.
- “Coronavirus (COVID-19) Vaccinations – Statistics and Research”. Our World in Data.
- “Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine”. World Health Organization. 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- Gates B (30 April 2020). “The vaccine race explained: What you need to know about the COVID-19 vaccine”. The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.
- Gates B (February 2020). “Responding to Covid-19: A once-in-a-century pandemic?”. The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.
- Weintraub R, Yadav P, Berkley S (2 April 2020). “A COVID-19 vaccine will need equitable, global distribution”. Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
- Steenhuysen J, Eisler P, Martell A, Nebehay S (2020-04-27). “Special Report: Countries, companies risk billions in race for coronavirus vaccine”. Reuters. Archived from the original on 15 May 2020. Retrieved 2020-05-02.
- Gartner A, Roberts L (3 May 2020). “How close are we to a coronavirus vaccine? Latest news on UK trials”. The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. (9 April 2020). “The COVID-19 vaccine development landscape”. Nature Reviews Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
- Le TT, Cramer JP, Chen R, Mayhew S (4 September 2020). “Evolution of the COVID-19 vaccine development landscape”. Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.
- Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). “Ensuring global access to COVID‑19 vaccines”. Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778.
CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
- “An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial” (PDF). World Health Organization. 9 April 2020. Archived (PDF) from the original on 12 May 2020. Retrieved 9 May 2020.
- “COVAX: Ensuring global equitable access to COVID-19 vaccines”. GAVI. 2020. Archived from the original on 25 September 2020. Retrieved 28 August 2020.
- “R&D Blueprint: A coordinated global research roadmap – 2019 novel coronavirus” (PDF). World Health Organization. 1 March 2020. Archived (PDF) from the original on 15 May 2020. Retrieved 10 May 2020.
- Tepperman, Jonathan (2021-01-28). “The global vaccine rollout is failing — and that puts everyone, everywhere, in danger”. Foreign Policy. Retrieved 2021-04-25.
- Ellyatt, Holly (2021-03-30). “Mutations could render current Covid vaccines ineffective in a year or less, epidemiologists warn”. CNBC. Retrieved 2021-04-25.
- “Coronavirus (COVID-19) Vaccinations”. Our World in Data. Sourced from individual health agencies.
- “COVID Data Tracker”. Centers for Disease Control and Prevention.
- “Ministry of Health – Palau on Instagram: “Palau MOH COVID-19 SitRep – 24 May 2021““. Instagram. Retrieved 2021-05-29.
- “Rome homeless get free COVID-19 shots – and a visit from the Pope”. Reuters. 2021-04-23. Retrieved 2021-05-29.
- “COVID-19 Vaccination Campaign Continues” (Press release). Government of Ascension Island. 25 March 2021.
- Kilpatrick, Fiona. “Covid-19 vaccinations Start on Tristan”. http://www.tristandc.com. Retrieved 2021-05-29.
- “Covid-19 vaccine: who are countries prioritising for first doses?”. the Guardian. November 18, 2020.
- Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. (December 2020). “The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine – United States, 2020” (PDF). MMWR Morb Mortal Wkly Rep. 69 (49): 1857–9. doi:10.15585/mmwr.mm6949e1. PMC 7737687. PMID 33301429.
- Dooling, Kathleen (2021). “The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020”. MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1657–1660. doi:10.15585/mmwr.mm695152e2. ISSN 0149-2195. PMID 33382671.
- Sun LH, Stanley-Becker I. “Health-care workers and nursing home residents should be the first to get coronavirus vaccines, CDC advisory group says”. The Washington Post. Retrieved 3 December 2020.
- “Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK”. European Centre for Disease Prevention and Control. 2020-12-02. Retrieved 2021-01-01.
- Pietsch B (2020-12-27). “E.U. Starts Effort to Vaccinate 450 Million”. The New York Times. Retrieved 2021-01-01.
- “Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020”. GOV.UK. Retrieved 2021-01-02.
- Plotkin, S. A.; Halsey, N. (2021). “Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines”. Oxford Academic. doi:10.1093/cid/ciab068. PMC 7929065. PMID 33502467.
- Epperly, David (2021). “Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing”. SSRN. doi:10.2139/ssrn.3760833.
- Absalon J, Koury K, Gruber W (February 17, 2021). “Correspondence: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”. New England Journal of Medicine. doi:10.1056/NEJMc2036242.
- “More Evidence: Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing”. ReallyCorrect.com.
- Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. (March 10, 2021). “Correspondence: Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine”. New England Journal of Medicine. 384 (14): 1372–1374. doi:10.1056/NEJMc2101667. PMC 8008743. PMID 33691060.
- Frishberg, Hannah (April 16, 2021). “Man accidentally gets one Moderna and one Pfizer COVID vaccine”. NY Post.
- “Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States”. CDC.
- “COVAX: Working for global equitable access to COVID-19 vaccines”. World Health Organization. 2020. Retrieved 18 December 2020.
- “COVAX announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021”. World Health Organization. 18 December 2020. Retrieved 18 December 2020.
- Mullard, Asher (30 November 2020). “How COVID vaccines are being divvied up around the world Canada leads the pack in terms of doses secured per capita”. Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811. Retrieved 11 December 2020.
- So, Anthony D; Woo, Joshua (December 15, 2020). “Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis”. The BMJ. 371: m4750. doi:10.1136/bmj.m4750. PMC 7735431. PMID 33323376.
- “Coronavirus: WHO chief criticizes ‘shocking’ global vaccine divide”. BBC. 2021-04-10. Retrieved 2021-04-25.
- “Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all”. Global Alliance for Vaccines and Immunisation. 4 June 2020. Archived from the original on 6 June 2020. Retrieved 4 June 2020.
- Wake D (4 May 2020). “EU spearheads $8 billion virus fundraiser”. Yahoo! Finance. Archived from the original on 29 June 2020. Retrieved 4 May 2020.
- Bollyky TJ, Gostin LO, Hamburg MA (7 May 2020). “The equitable distribution of COVID-19 therapeutics and vaccines”. JAMA. 323 (24): 2462–63. doi:10.1001/jama.2020.6641. PMID 32379268.
- Huneycutt B, Lurie N, Rotenberg S, Wilder R, Hatchett R (24 February 2020). “Finding equipoise: CEPI revises its equitable access policy”. Vaccine. 38 (9): 2144–48. doi:10.1016/j.vaccine.2019.12.055. PMC 7130943. PMID 32005536.
- “COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert”. CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.
- “Vaccine for COVID-19”. The Center for Artistic Activism. 22 March 2020. Archived from the original on 9 June 2020. Retrieved 8 June 2020.
- “UAEM response to COVID-19”. Universities Allied for Essential Medicines. 2020. Archived from the original on 21 April 2020. Retrieved 9 June 2020.
- McCann, Allison; Gamio, Lazaro (2021-03-19). “Who Can and Can’t Get Vaccinated Right Now”. The New York Times. ISSN 0362-4331. Retrieved 2021-03-27.
- COVIDSurg Collaborative, GlobalSurg Collaborative (2021-03-24). “SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study”. British Journal of Surgery: znab101. doi:10.1093/bjs/znab101. ISSN 0007-1323. PMC 7995808. PMID 33761533.
- Rodríguez, Pau (14 January 2021). “Por qué las dosis sobrantes de la vacuna pueden ser un nuevo rompecabezas”. ElDiario.es (in Spanish). Retrieved 15 January 2021.
- Stevenson, Peter (24 March 2021). “Biden’s vaccination success story is about to run into a world of pressure”. Washington Post. Retrieved 7 April 2021.
- Dewan, Angela (15 April 2021). “The US could have 300M extra vaccines. Why won’t it share?”. CNN. Retrieved 15 April 2021.
- Eban, Katherine (April 6, 2021). “‘We Are Hoarding’: Why the U.S. Still Can’t Donate COVID-19 Vaccines to Countries in Need”. Vanity Fair. Condé Nast. Retrieved 7 April 2021.
- Ferrucci A. (5 May 2020). “More than 100 scientists call for Covid 19 vaccines to be in the public domain” Archived 14 August 2020 at the Wayback Machine. edc.online.org. Retrieved 21 July 2020.
- “Patently absurd”. Corporate Europe Observatory. 2021-03-11. Retrieved 2021-03-13.
- Pareene, Alex (March 15, 2021). “Most of the World Has a Simple Vaccine Request. America Isn’t Listening”. The New Republic.
- “It’s time to consider a patent reprieve for COVID vaccines”. Nature. 592 (7852): 7. 2021-03-30. Bibcode:2021Natur.592….7.. doi:10.1038/d41586-021-00863-w. PMID 33785920.
- Macias, Amanda; Breuninger, Kevin (May 5, 2021). “U.S. backs waiving patent protections for Covid vaccines, citing global health crisis”. CNBC.
- Pietromarchi, Virginia (2021-03-01). “Patently unfair: Can waivers help solve COVID vaccine inequality?”. Al Jazeera. Retrieved 2021-04-26.
Silverman, Rachel (March 15, 2021). “Waiving vaccine patents won’t help inoculate poorer nations: Voluntary licenses are a more promising way to get vaccines to the developing world”. The Washington Post.